At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

Citi has started coverage of Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) at buy saying the former will benefit from short-term growth of Biktarvy (bictegravir, emtricitabine ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), ...

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

biotechnology company said, adding that it looks forward to sharing topline data from a Phase 2 study later this year. Amgen is testing MariTide as a once-monthly shot, making it a promising potential ...

Amgen’s share price fell 7% in the wake of Brayer’s note, wiping $12 billion off the biotech’s market cap. However, Jefferies ...

TD Cowen analyst Yaron Werber has maintained their bullish stance on IOBT stock, giving a Buy rating yesterday. Yaron Werber has given his Buy ...